Delegation of China Council for the promotion of drugs visited the French pharmaceutical enterprises association and the headquarters of Sanofi (Europe visit series 4)

Source: China pharmaceutical innovation promotion association on July 30, 2017, song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as China pharmaceutical promotion association), led a delegation of China pharmaceutical promotion association to visit LEEM and Sanofi pharmaceutical company headquarters in Paris, France In the morning, the delegation visited LEEM Philippe Lamoureux, director general of LEEM and Pierre, director of global cooperation Savart, Christelle Marechal, director of European affairs and external relations, Damien dorizon, head of economic affairs, chairman of rdpac, Eric bouteiller, senior vice president of Asia operations of Yipu group, benoitcolinot, senior business officer of French Embassy in China, Olivier Fontaine, head of European and international affairs of French medicen company, Chloe Evans, project director of French biotechnology company, etc I received the delegation At the meeting with LEEM representatives, song Ruilin, executive chairman, and Philippe Lamoureux, general manager of LEEM, introduced the situation of French pharmaceutical industry to the participants At present, France is the second largest pharmaceutical market in Europe and the fifth largest pharmaceutical market in the world The annual investment in pharmaceutical research and development is about 4.5 billion euros, accounting for 10% of the total sales Clinical trials focused on tumors, allergic diseases, infectious diseases and rare diseases In 2015, 928 clinical trials were approved, an increase of 107 items compared with 821 clinical trials in 2014 In 2016, 10% of global clinical trials were conducted in France LEEM, as an industry organization of French pharmaceutical enterprises, is the governing body of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Its purpose is to strengthen industry norms and self-discipline, promote drug innovation to meet the needs of patients, and enhance the competitiveness of France in the field of drug R & D and production With 270 member companies and 100000 employees, the association invests 4.5-5 billion euros in new drug research and development every year, and their turnover accounts for 95% of the French pharmaceutical market Song Ruilin, executive chairman of the delegation, introduced the members of the delegation to the representative of LEEM, and said that CFDA is committed to building a diversified international exchange platform, promoting the innovation and development of China's pharmaceutical industry, and providing high-quality services to member units At the same time, China Council for the promotion of drugs has established a very close relationship with the industry and the government, actively participated in the system reform of the state to encourage innovation and deepen medical reform, put forward more constructive opinions and suggestions to encourage innovation, and promote the drug regulatory policy to be in line with the international standards The two sides held in-depth discussions on the current development of the pharmaceutical market, pharmaceutical policies and medical insurance system of the two countries Damien dorizon, director of LEEM's economic affairs, said that France is a country with a high level of medical insurance, but in recent five years, the government has strictly controlled the price of drugs in order to control the excessive growth of medical and health costs After the drug is approved for marketing, it is necessary to submit the technical report and economic report of the drug to the transparency Committee and pricing Committee of the French Health Assessment Agency (has), evaluate according to the scientific value of the drug, and decide whether to reimburse the drug and the reimbursement ratio according to the optimization degree of the drug Then it is submitted to the Economic Committee (CEPs) to decide the price of the drug, which needs to be reevaluated every five years 。 Philippe Lamoureux, general manager of LEEM, said that he hoped to establish a regular exchange mechanism with the China Council for the promotion of drugs, so as to better and more timely understand the pharmaceutical development of the two countries; at the same time, he hoped to establish long-term cooperation, hold pharmaceutical related activities, and enhance the exchanges and cooperation between the two countries President Song Ruilin gave a positive response to this proposal and looked forward to working together to promote exchanges between the two sessions On the afternoon of the 30th, the delegation visited Sanofi's headquarters, and held talks with Matthieu Merlin, vice president of BD in Asia, Clotilde Jolivet, director of partnership department, Laure lomo, French market access department and Ren Weiwei, vice director of public affairs of Sanofi's Chinese enterprises Meeting site with Sanofi representative During the meeting, Matthieu Merlin, vice president of BD of Sanofi China Asia region, introduced Sanofi's development process, development strategy and drug innovation and R & D to the delegation; Laure lomo, French market access department, made a detailed report on French medical insurance system and system; representatives at the meeting had a heated discussion on French medical insurance policy, pharmaceutical innovation environment and other issues Ouyang Jingbo, President and vice chairman of Wuzhou Zhongheng group, Wu Yulan, vice president of Jiangsu Haosen pharmaceutical, Jiang Hua, vice president of LVYE Pharmaceutical Group, Ke Xiao, vice president of Kanghong Pharmaceutical Group, he Yun, general manager of Liangjiang pharmaceutical R & D center, Gu Hongmei, president assistant and vice president of Research Institute of Zhengda Tianqing pharmaceutical, Cheng Yinqi, Deputy Secretary General of China Pharmaceutical Council, Lu Xiaoti, vice director of international department and other Chinese Drugs Members of the delegation attended today's event.